David Nicholas Gee Sells 4,323 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 4,323 shares of Cellebrite DI stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at $1,536,792.16. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Nicholas Gee also recently made the following trade(s):

• On Friday, August 21st, David Nicholas Gee sold 2,198 shares of Cellebrite DI stock. The shares were sold at an average price of $11.24, for a total value of $24,705.52.
• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total transaction of $3,696.10.

Cellebrite DI Trading Up 2.9%

Shares of CLBT stock opened at $11.62 on Thursday. Cellebrite DI Ltd. has a 12-month low of $9.58 and a 12-month high of $19.98. The firm’s 50 day moving average is $14.19 and its 200 day moving average is $13.80. The stock has a market capitalization of $2.90 billion, a P/E ratio of 52.82, a P/E/G ratio of 1.73 and a beta of 1.18.

Key Cellebrite DI News

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite launched the Portable Tactical Extraction Kit (C-TEK), a field-deployable digital-forensics solution for armed forces. The kit enables forward-deployed teams to rapidly triage data from phones, SIM cards, drones and portable media, expanding Cellebrite’s addressable market in defense and battlefield intelligence. C-TEK launch announcement
• Positive Sentiment: The announcement reinforces Cellebrite’s positioning as a provider of AI-enabled digital investigation and intelligence tools for governments, law enforcement and enterprises. Any adoption by military customers could support longer-term revenue growth, although the release did not disclose contracts or financial targets.
• Neutral Sentiment: Analyst opinion remains broadly constructive, with five Buy ratings and one Sell rating and a consensus price target of $16.70. However, JPMorgan, DA Davidson, Lake Street and Needham recently lowered their targets, signaling more cautious expectations after the stock’s decline.
• Neutral Sentiment: Reported short interest was zero shares, producing no meaningful short-interest signal. The data also contained an anomalous percentage-change figure, limiting its usefulness for assessing near-term trading pressure.
• Negative Sentiment: Kaplan Fox & Kilsheimer announced an investigation into potential securities-law violations involving Cellebrite. The announcement does not establish wrongdoing, but it adds legal, reputational and potential litigation risk that could weigh on investor sentiment. Kaplan Fox investigation
• Negative Sentiment: Chief Marketing Officer David Nicholas Gee sold 4,323 shares for approximately $49,100, following a sale of 2,198 shares worth about $24,700 several days earlier. The latest transaction was made under a pre-arranged Rule 10b5-1 plan and leaves him with a substantial holding, but repeated executive sales may still pressure sentiment. Insider sale filing

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Voss Capital LP boosted its stake in Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after purchasing an additional 1,277,300 shares during the period. Pertento Partners LLP raised its position in shares of Cellebrite DI by 28.2% during the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after buying an additional 1,311,109 shares during the last quarter. Invesco Ltd. raised its position in shares of Cellebrite DI by 0.8% during the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after buying an additional 43,041 shares during the last quarter. Granahan Investment Management LLC lifted its holdings in shares of Cellebrite DI by 16.3% in the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after buying an additional 427,719 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Cellebrite DI by 93.7% in the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after buying an additional 1,475,579 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Lake Street Capital reduced their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings downgraded shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. decreased their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Finally, DA Davidson dropped their target price on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.